Search

You searched for "stone"

1377 results found
Journal of Pediatric Urology cover image.

Health-related quality of life in men with corrected hypospadias

1 March 2014 | | URO - Paediatrics
More and more studies on long-term outcomes of paediatric operations are being published, many of which concentrate on health-related quality of life (HRQol) scores. This paper compared 45 men with corrected hypospadias (mean age 26.2 years +/- 5.1 years) with...
Prostate Cancer and Prostatic Diseases cover image.

The natural history of prostate cancer on MRI

1 September 2019 | | URO - Urologic Oncology, URO - Uroradiology
Multiparametric MRI features heavily on a number of active surveillance protocols. This study looked at 86 men on active surveillance who had an mpMRI prior to 2013 to assess how lesions changed over time. Two blinded radiologists examined all the...
The Journal of Urology cover image.

Refining management of non-visible haematuria

2 March 2022 | | URO - Functional / Reconstructive Urology, URO - Infection, URO - Urologic Oncology
The optimal evaluation of non-visible haematuria (NVH) continues to be debated, with competing interests of avoidance underdiagnosis and the harms of over-testing. Current National Institute for Health & Care Excellent (NICE) guidance recommends referral for patients ≥60 years with NVH....

Becoming a consultant: Navigating the next step in your career

7 May 2026 | | URO - Core Urology
For senior urology trainees approaching their final ARCP, one question often looms large: what next? Some pursue a fellowship, while others may take some time out. Ultimately, however, all trainees face the inevitable transition: stepping into a consultant post. This...

RSM Paediatric Urology Meeting and Presidential Address 2023

4 March 2024 | | URO - Paediatrics
The academic year of the Urological Section of the Royal Society of Medicine (RSM) started with a bang in October last year with the Paediatric Urology meeting, co-organised by Shabnam Undre (Paediatric Representative for BAUS and Consultant Paediatric Urologist East...

Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction

3 September 2021 | | URO - Urologic Oncology
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...

Prostate cancer

8 November 2021 | | URO - Urologic Oncology
Case 1 A 65-year-old man is referred to your two-week wait (2WW) clinic with a PSA of 7.0ng/mL. He has no lower urinary tract symptoms (LUTS), no past medical history, no family history of prostate cancer (PCa) and his performance...

Rishi Sunak joins Prostate Cancer Research as an ambassador

26 February 2025 | Charities, Research & Development
Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...

The multidisciplinary team meeting: London calling!

1 January 2015 | | URO - Technology
The multidisciplinary team meeting, or MDT, is the foundation of cancer management in the UK. The MDT consists of a group of experts in different fields of medicine and surgery coming together at regular intervals to discuss the diagnosis and...

Recent advances in the management of castration resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

3 March 2021 | | URO - Urologic Oncology, URO - Technology
The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...